SCHEMBL18160911

SCHEMBL18160911

CCOC(=O)/C=C/c1c(NS(=O)(=O)c2cccs2)cc2c(ncn2C)c1F

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 11/20 0.55
AKT1 P31749 4/20 0.55
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.39
TNF P01375 1/20 0.39
MAPK1 P28482 1/20 0.39
NOD2 Q9HC29 1/20 0.39
NOD1 Q9Y239 1/20 0.39
HIF1A Q16665 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
PLK1 P53350 1/20 0.38
CCR2 P41597 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18148080 0.88 CNKSR1 (0.51) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18148082 0.88 CNKSR1 (0.51) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18163759 0.84 CNKSR1 (0.38) CNKSR1AKT1ALDH1A1MEN1KMT2A
SCHEMBL18148026 0.83 CNKSR1 (0.56) CNKSR1AKT1ALDH1A1MAPTKMT2A
SCHEMBL18147978 0.83 ALDH1A1 (0.42) CNKSR1AKT1ALDH1A1MEN1MAPT
SCHEMBL18148027 0.83 CNKSR1 (0.56) CNKSR1AKT1ALDH1A1MAPTKMT2A
SCHEMBL18148020 0.82 ALDH1A1 (0.42) CNKSR1AKT1ALDH1A1MEN1MAPT
SCHEMBL18160894 0.77 CNKSR1 (0.80) CNKSR1AKT1ALDH1A1MEN1MAPT
SCHEMBL15888942 0.75 CNKSR1 (0.65) CNKSR1AKT1ALDH1A1MEN1MAPT
SCHEMBL18148051 0.74 CNKSR1 (0.44) CNKSR1ALDH1A1MAPTKMT2ATNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
WO-2016172191-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-27 WO disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885ALDH1A1 4731/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885ALDH1A1 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.